{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:49:28Z","timestamp":1777492168847,"version":"3.51.4"},"reference-count":155,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"European Alliance of Associations for Rheumatology"},{"DOI":"10.13039\/100019016","name":"Assessment of SpondyloArthritis international Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1136\/ard-2022-223296","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T13:55:12Z","timestamp":1666360512000},"page":"19-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":807,"title":["ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-3726","authenticated-orcid":false,"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1954-0229","authenticated-orcid":false,"given":"Alexandre","family":"Sepriano","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-0939","authenticated-orcid":false,"given":"Augusta","family":"Ortolan","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-8547","authenticated-orcid":false,"given":"Casper","family":"Webers","sequence":"additional","affiliation":[]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0577-6620","authenticated-orcid":false,"given":"Robert B M","family":"Landew\u00e9","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5932","authenticated-orcid":false,"given":"Filip E","family":"Van den Bosch","sequence":"additional","affiliation":[]},{"given":"Boryana","family":"Boteva","sequence":"additional","affiliation":[]},{"given":"Ann","family":"Bremander","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9254-6171","authenticated-orcid":false,"given":"Philippe","family":"Carron","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-7132","authenticated-orcid":false,"given":"Adrian","family":"Ciurea","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-7407","authenticated-orcid":false,"given":"Floris A","family":"van Gaalen","sequence":"additional","affiliation":[]},{"given":"P\u00e1l","family":"G\u00e9her","sequence":"additional","affiliation":[]},{"given":"Lianne","family":"Gensler","sequence":"additional","affiliation":[]},{"given":"Josef","family":"Hermann","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0652-9808","authenticated-orcid":false,"given":"Manouk","family":"de Hooge","sequence":"additional","affiliation":[]},{"given":"Marketa","family":"Husakova","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-4497","authenticated-orcid":false,"given":"Uta","family":"Kiltz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-5837","authenticated-orcid":false,"given":"Clementina","family":"L\u00f3pez-Medina","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-7972","authenticated-orcid":false,"given":"Pedro M","family":"Machado","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-1986","authenticated-orcid":false,"given":"Anna","family":"Molto","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6326-1764","authenticated-orcid":false,"given":"Michael J","family":"Nissen","sequence":"additional","affiliation":[]},{"given":"Fernando M","family":"Pimentel-Santos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-6015","authenticated-orcid":false,"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-033X","authenticated-orcid":false,"given":"Fabian","family":"Proft","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-548X","authenticated-orcid":false,"given":"Martin","family":"Rudwaleit","sequence":"additional","affiliation":[]},{"given":"Mark","family":"Telkman","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-7353","authenticated-orcid":false,"given":"Sizheng Steven","family":"Zhao","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4479-7678","authenticated-orcid":false,"given":"Nelly","family":"Ziade","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223296_bib1","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","article-title":"Axial spondyloarthritis","volume":"80","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib2","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2019-215707","article-title":"Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? results from eight cohorts","volume":"78","author":"Boel","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib3","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/art.20990","article-title":"The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?","volume":"52","author":"Rudwaleit","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223296_bib4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of spondyloarthritis International Society classification criteria for axial spondyloarthritis (Part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib5","doi-asserted-by":"crossref","first-page":"e001108","DOI":"10.1136\/rmdopen-2019-001108","article-title":"Characteristics and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis: a comparison by systematic literature review and meta-analysis","volume":"5","author":"L\u00f3pez-Medina","year":"2019","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223296_bib6","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/rheumatology\/kez171","article-title":"Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States","volume":"58","author":"Zhao","year":"2019","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2015-208852","article-title":"The term 'non-radiographic axial spondyloarthritis\u2019 is much more important to classify than to diagnose patients with axial spondyloarthritis","volume":"75","author":"Deodhar","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","article-title":"ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib10","first-page":"896","article-title":"Update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"2011","author":"Braun","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib11","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib13","author":"Webers","year":"2022","journal-title":"Efficacy and safety of biological DMARDs: a systematic literature review Informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis"},{"key":"10.1136\/ard-2022-223296_bib14","author":"Ortolan","year":"2022","journal-title":"Efficacy and safety of non-pharmacological and pharmacological non-biological interventions: a systematic literature review Informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis"},{"key":"10.1136\/ard-2022-223296_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.2005.041129","article-title":"Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib16","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/rheumatology\/kes066","article-title":"First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis","volume":"51","author":"van den Berg","year":"2012","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib17","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/rheumatology\/kes026","article-title":"Update of the literature review on treatment with biologics as a basis for the first update of the ASAS\/EULAR management recommendations of ankylosing spondylitis","volume":"51","author":"Baraliakos","year":"2012","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib18","doi-asserted-by":"crossref","first-page":"e000396","DOI":"10.1136\/rmdopen-2016-000396","article-title":"Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review Informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Sepriano","year":"2017","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223296_bib19","doi-asserted-by":"crossref","first-page":"e000397","DOI":"10.1136\/rmdopen-2016-000397","article-title":"Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review Informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Regel","year":"2017","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223296_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib21","author":"Oxford Centre for Evidence-Based Medicine"},{"key":"10.1136\/ard-2022-223296_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib23","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1136\/ard.2011.150037","article-title":"A stratified model for health outcomes in ankylosing spondylitis","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/rheumatology\/keaa353","article-title":"Determinants of the patient global assessment of well-being in early axial spondyloarthritis: 5-year longitudinal data from the DESIR cohort","volume":"60","author":"Hirano","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib25","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib26","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/ard.2008.091793","article-title":"Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine","volume":"68","author":"Landew\u00e9","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib27","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1136\/annrheumdis-2016-209209","article-title":"High disease activity according to the ankylosing spondylitis disease activity score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the German spondyloarthritis inception cohort","volume":"75","author":"Poddubnyy","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib28","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/annrheumdis-2021-220249","article-title":"EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis","volume":"2021","author":"Nikiphorou","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pec.2011.02.004","article-title":"Patient preferences for shared decisions: a systematic review","volume":"86","author":"Chewning","year":"2012","journal-title":"Patient Educ Couns"},{"key":"10.1136\/ard-2022-223296_bib30","first-page":"S112","article-title":"The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis","volume":"27","author":"Boonen","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib31","doi-asserted-by":"crossref","first-page":"e000259","DOI":"10.1136\/rmdopen-2016-000259","article-title":"Costs of drugs for treatment of rheumatic diseases","volume":"2","author":"Westhovens","year":"2016","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223296_bib32","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.semarthrit.2021.07.021","article-title":"The ASAS-OMERACT core domain set for axial spondyloarthritis","volume":"51","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223296_bib33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fmed.2018.00062","article-title":"Comorbidities in spondyloarthritis","volume":"5","author":"Molt\u00f3","year":"2018","journal-title":"Front Med"},{"key":"10.1136\/ard-2022-223296_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international Task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib35","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jbspin.2019.07.007","article-title":"Performance of the ankylosing spondylitis disease activity score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis","volume":"87","author":"Proft","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard-2022-223296_bib38","doi-asserted-by":"crossref","first-page":"221085951","DOI":"10.1177\/1759720X221085951","article-title":"Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial spa: a prospective multicentre cross-sectional study","volume":"14","author":"Proft","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2022-223296_bib39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/rheumatology\/keaa564","article-title":"Disease activity is associated with spinal radiographic progression in axial spondyloarthritis independently of exposure to tumour necrosis factor inhibitors","volume":"60","author":"Sepriano","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2017-212178","article-title":"An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS","volume":"77","author":"Molto","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"10.1136\/ard-2022-223296_bib42","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","article-title":"The assessment of spondyloarthritis International Society (ASAS) Handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib43","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2011-200508","article-title":"The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study","volume":"71","author":"Kiltz","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib44","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/annrheumdis-2013-203967","article-title":"Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS","volume":"74","author":"Kiltz","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib45","doi-asserted-by":"crossref","first-page":"e000302","DOI":"10.1136\/rmdopen-2016-000302","article-title":"Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools","volume":"2","author":"van Riel","year":"2016","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223296_bib46","doi-asserted-by":"crossref","first-page":"e002106","DOI":"10.1136\/rmdopen-2021-002106","article-title":"Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France","volume":"8","author":"Dougados","year":"2022","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223296_bib47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/annrheumdis-2019-216034","article-title":"Development of ASAS quality Standards to improve the quality of health and care services for patients with axial spondyloarthritis","volume":"79","author":"Kiltz","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib48","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/annrheumdis-2015-207786","article-title":"Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort","volume":"75","author":"Navarro-Comp\u00e1n","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib49","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/annrheumdis-2016-210697","article-title":"In patients with axial spondyloarthritis, inflammation on MRI of the spine is longitudinally related to disease activity only in men: 2 years of the axial spondyloarthritis DESIR cohort","volume":"77","author":"Navarro-Comp\u00e1n","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib50","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/annrheumdis-2012-201999","article-title":"Mri inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor","volume":"71","author":"Machado","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib51","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2013-204055","article-title":"Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study","volume":"74","author":"Ramiro","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib52","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/annrheumdis-2011-200411","article-title":"Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study","volume":"71","author":"van Tubergen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib53","first-page":"997","article-title":"Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year","volume":"26","author":"Spoorenberg","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib54","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","article-title":"Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial","volume":"80","author":"Molto","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2021-222020","article-title":"2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases","volume":"82","author":"Gwinnutt","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib56","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/annrheumdis-2014-206807","article-title":"EULAR recommendations for patient education for people with inflammatory arthritis","volume":"74","author":"Zangi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib57","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1136\/annrheumdis-2018-213585","article-title":"EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis","volume":"2018","author":"Rausch Osthoff","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002822.pub3","article-title":"Physiotherapy interventions for ankylosing spondylitis","author":"Dagfinrud","year":"2008","journal-title":"The Cochrane database of systematic reviews"},{"key":"10.1136\/ard-2022-223296_bib59","doi-asserted-by":"crossref","first-page":"e20019","DOI":"10.1097\/MD.0000000000020019","article-title":"Efficacy of needle-knife combined with etanercept treatment regarding disease activity and hip joint function in ankylosing spondylitis patients with hip joint involvement: a randomized controlled study","volume":"99","author":"You","year":"2020","journal-title":"Medicine"},{"key":"10.1136\/ard-2022-223296_bib60","doi-asserted-by":"crossref","first-page":"100952","DOI":"10.1016\/j.eujim.2019.100952","article-title":"Moxibustion therapy in Chinese patients with ankylosing spondylitis: a randomized controlled pilot trial","volume":"31","author":"Wang","year":"2019","journal-title":"Eur J Integr Med"},{"key":"10.1136\/ard-2022-223296_bib61","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/art.33465","article-title":"Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis","volume":"64","author":"Poddubnyy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223296_bib62","doi-asserted-by":"crossref","first-page":"e000153","DOI":"10.1136\/rmdopen-2015-000153","article-title":"Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis","volume":"1","author":"Ramiro","year":"2015","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223296_bib63","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/annrheumdis-2011-200180","article-title":"Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort","volume":"71","author":"Chung","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib64","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/art.41408","article-title":"Do smoking and socioeconomic factors influence imaging outcomes in axial spondyloarthritis? Five\u2010Year data from the DESIR cohort","volume":"72","author":"Nikiphorou","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib65","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/art.39666","article-title":"Rate and predisposing factors for Sacroiliac joint radiographic progression after a Two\u2010Year Follow\u2010up period in Recent\u2010Onset spondyloarthritis","volume":"68","author":"Dougados","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib66","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib67","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223296_bib68","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","article-title":"Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis","volume":"71","author":"Kroon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib69","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German spondyloarthritis inception cohort","volume":"71","author":"Poddubnyy","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib70","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2\u2005years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib71","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/rheumatology\/kes032","article-title":"Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3E initiative","volume":"51","author":"Whittle","year":"2012","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib72","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/annrheumdis-2017-212662","article-title":"EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis","volume":"77","author":"Geenen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib73","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/art.1780350512","article-title":"Corticosteroid injection of the sacroiliac joint in patients with seronegative spondylarthropathy","volume":"35","author":"Maugars","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223296_bib74","first-page":"88","article-title":"Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy","volume":"17","author":"Luukkainen","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib75","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/annrheumdis-2012-203055","article-title":"Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial","volume":"73","author":"Haibel","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib76","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/rheumatology\/keaa685","article-title":"Efficacy of a step-down regimen of oral prednisolone in axial spondyloarthritis: result of a double-blind randomized controlled trial (COBRA-AS study)","volume":"60","author":"Mishra","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004800.pub3","article-title":"Sulfasalazine for ankylosing spondylitis","author":"Chen","year":"2014","journal-title":"The Cochrane database of systematic reviews"},{"key":"10.1136\/ard-2022-223296_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004524.pub4","article-title":"Methotrexate for ankylosing spondylitis","author":"Chen","year":"2013","journal-title":"The Cochrane database of systematic reviews"},{"key":"10.1136\/ard-2022-223296_bib79","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/ard.2006.054098","article-title":"No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial","volume":"66","author":"Haibel","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib80","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/rheumatology\/kex514","article-title":"Adherence to recommendations for the use of anti-tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis","volume":"57","author":"L\u00f3pez-Medina","year":"2018","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib81","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223296_bib82","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry","volume":"69","author":"Glintborg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib83","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2007.073098","article-title":"Mri in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis","volume":"67","author":"Rudwaleit","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib84","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib85","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib86","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib87","doi-asserted-by":"crossref","first-page":"e002067","DOI":"10.1136\/rmdopen-2021-002067","article-title":"Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort","volume":"8","author":"Ciurea","year":"2022","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223296_bib89","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2010.133488","article-title":"ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials\/epidemiological studies in axial spondyloarthritis","volume":"70","author":"Dougados","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib90","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/rheumatology\/kes057","article-title":"Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria","volume":"51","author":"Fagerli","year":"2012","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib91","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.reuma.2013.12.006","article-title":"ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy","volume":"10","author":"Vastesaeger","year":"2014","journal-title":"Reumatol Clin"},{"key":"10.1136\/ard-2022-223296_bib92","doi-asserted-by":"crossref","first-page":"e001145","DOI":"10.1136\/rmdopen-2019-001145","article-title":"Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI","volume":"6","author":"Marona","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223296_bib93","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib94","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223296_bib95","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.38974","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib","volume":"67","author":"Charles-Schoeman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib96","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","article-title":"Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223296_bib97","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223296_bib98","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib99","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/art.41911","article-title":"Safety and efficacy of Upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension","volume":"74","author":"Deodhar","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib100","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223296_bib101","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223296_bib102","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3899\/jrheum.131289","article-title":"Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis","volume":"41","author":"van Denderen","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib103","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.22848","article-title":"Observed incidence of uveitis following Certolizumab pegol treatment in patients with axial spondyloarthritis","volume":"68","author":"Rudwaleit","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223296_bib104","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","article-title":"Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials","volume":"69","author":"Sieper","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate","volume":"121","author":"Foster","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1136\/ard-2022-223296_bib106","doi-asserted-by":"crossref","first-page":"e001161","DOI":"10.1136\/rmdopen-2019-001161","article-title":"The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW","volume":"6","author":"van der Horst-Bruinsma","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223296_bib107","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3899\/jrheum.180312","article-title":"Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab - The GO-EASY Study","volume":"46","author":"van Bentum","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib108","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib109","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2021-220420","article-title":"Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?","volume":"80","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1136\/ard-2022-223296_bib111","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1136\/ard-2022-223296_bib112","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1136\/ard-2022-223296_bib113","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the accent I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223296_bib114","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the classic II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1136\/ard-2022-223296_bib115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223296_bib116","article-title":"Pharmacokinetics and exposure-response relationship of golimumab in patients with Moderately-to-Severely active ulcerative colitis: results from phase 2\/3 pursuit induction and maintenance studies","author":"Adedokun","year":"2016","journal-title":"Journal of Crohn's & colitis"},{"key":"10.1136\/ard-2022-223296_bib117","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (exceed): a double-blind, parallel-group, randomised, active-controlled, phase 3B trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223296_bib118","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib119","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/annrheumdis-2018-213700","article-title":"Overdiagnosis and overtreatment in rheumatology: a little caution is in order","volume":"77","author":"Landew\u00e9","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib120","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1093\/rheumatology\/keab242","article-title":"Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis","volume":"60","author":"Zhao","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib121","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1093\/rheumatology\/keaa768","article-title":"Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS","volume":"60","author":"Zhao","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib122","doi-asserted-by":"crossref","first-page":"iv47","DOI":"10.1093\/rheumatology\/keaa246","article-title":"Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis","volume":"59","author":"Zhao","year":"2020","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib123","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/rheumatology\/kez119","article-title":"Comorbidity burden in axial spondyloarthritis: a cluster analysis","volume":"58","author":"Zhao","year":"2019","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib124","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13075-018-1644-6","article-title":"The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis","volume":"20","author":"Zhao","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223296_bib125","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13075-016-0943-z","article-title":"Evaluation of the impact of fibromyalgia in disease activity and treatment effect in spondyloarthritis","volume":"18","author":"Bello","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223296_bib126","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/annrheumdis-2017-212378","article-title":"Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study","volume":"77","author":"Molt\u00f3","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib127","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.2010.131797","article-title":"Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register","volume":"70","author":"Lie","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib129","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III measure 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib130","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the measure 2 study","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib131","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, measure 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223296_bib132","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2022-223296_bib133","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223296_bib134","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib135","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","article-title":"Anti-Tnf discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review","volume":"55","author":"Navarro-Comp\u00e1n","year":"2016","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib136","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3899\/jrheum.141335","article-title":"Is etanercept 25 Mg once Weekly as effective as 50 Mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial","volume":"42","author":"Yates","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib137","first-page":"1","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study","volume":"7","author":"Cantini","year":"2013","journal-title":"Biologics"},{"key":"10.1136\/ard-2022-223296_bib138","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","article-title":"Non-Inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis","volume":"21","author":"Gratac\u00f3s","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223296_bib139","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","article-title":"Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib140","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/annrheumdis-2020-219717","article-title":"Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)","volume":"80","author":"Landew\u00e9","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib141","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/rheumatology\/kep174","article-title":"Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery","volume":"49","author":"Vander Cruyssen","year":"2010","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223296_bib142","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4055\/cios.2017.9.3.263","article-title":"Comparison of outcomes of total hip arthroplasty between patients with ankylosing spondylitis and avascular necrosis of the femoral head","volume":"9","author":"Lee","year":"2017","journal-title":"Clin Orthop Surg"},{"key":"10.1136\/ard-2022-223296_bib143","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/ard.58.7.399","article-title":"Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment","volume":"58","author":"Van Royen","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib144","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13018-019-1170-5","article-title":"Comparison of loss of correction between PSO and VCD technique in treating thoracolumbar kyphosis secondary to ankylosing spondylitis, a minimum 2 years follow-up","volume":"14","author":"Wang","year":"2019","journal-title":"J Orthop Surg Res"},{"key":"10.1136\/ard-2022-223296_bib145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00586-008-0764-0","article-title":"Spinal fractures in patients with ankylosing spinal disorders: a systematic review of the literature on treatment, neurological status and complications","volume":"18","author":"Westerveld","year":"2009","journal-title":"Eur Spine J"},{"key":"10.1136\/ard-2022-223296_bib146","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2014-206971","article-title":"EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice","volume":"74","author":"Mandl","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib147","doi-asserted-by":"crossref","first-page":"700.1","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib148","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review Informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib149","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review Informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib150","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1016\/S2665-9913(21)00013-8","article-title":"The unsustainable bubble of disease-modifying antirheumatic drugs in rheumatology","volume":"3","author":"Landew\u00e9","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib151","doi-asserted-by":"crossref","first-page":"e001450","DOI":"10.1136\/rmdopen-2020-001450","article-title":"Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study","volume":"7","author":"L\u00f3pez-Medina","year":"2021","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223296_bib152","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3899\/jrheum.181331","article-title":"Peripheral manifestations in spondyloarthritis and their effect: an ancillary analysis of the ASAS-COMOSPA study","volume":"47","author":"L\u00f3pez-Medina","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223296_bib153","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13075-019-1927-6","article-title":"Evaluation of concomitant peripheral arthritis in patients with recent onset axial spondyloarthritis: 5-year results from the DESIR cohort","volume":"21","author":"L\u00f3pez-Medina","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223296_bib154","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/annrheumdis-2019-216516","article-title":"What is axial spondyloarthritis? a latent class and transition analysis in the space and DESIR cohorts","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223296_bib155","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"Update of the American College of Rheumatology\/Spondylitis association of America\/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and Nonradiographic axial spondyloarthritis","volume":"2019","author":"Ward","year":"2019","journal-title":"Arthritis & rheumatology"},{"key":"10.1136\/ard-2022-223296_bib156","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/ard-2022-223016","article-title":"Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and uptake","volume":"81","author":"Loza","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724086205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724086205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T09:26:04Z","timestamp":1749806764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724086205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":155,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0003496724086205"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223296","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}